Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm

L. Dostálek, M. Zikan, D. Fischerova, R. Kocian, A. Germanova, F. Frühauf, L. Dusek, J. Slama, P. Dundr, K. Nemejcova, D. Cibula,

. 2018 ; 148 (3) : 456-460. [pub] 20180201

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033370

Grantová podpora
NV16-31643A MZ0 CEP - Centrální evidence projektů

OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors<2cm, 2-3.9cm, and ≥4cm (79%, 83%, 76%) (P=0.460). There were only two cases with false-negative SLN ultrastaging for pelvic LN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P=0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P=0.510). CONCLUSIONS: If the tracer application technique is adjusted in larger tumors, SLN biopsy can be equally reliable in pelvic LN staging in tumors smaller and larger than 2cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors<2cm, 2-3.9cm, and ≥4cm.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033370
003      
CZ-PrNML
005      
20190304105957.0
007      
ta
008      
181008s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ygyno.2018.01.001 $2 doi
035    __
$a (PubMed)29366509
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dostálek, Lukáš, $d 1983- $7 xx0228314 $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
245    10
$a SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm / $c L. Dostálek, M. Zikan, D. Fischerova, R. Kocian, A. Germanova, F. Frühauf, L. Dusek, J. Slama, P. Dundr, K. Nemejcova, D. Cibula,
520    9_
$a OBJECTIVES: The aim of this study was to assess the detection rate, false-negative rate and sensitivity of SLN in LN staging in tumors over 2cm on a large cohort of patients. METHODS: Data from patients with stages pT1a - pT2 cervical cancer who underwent surgical treatment, including SLN biopsy followed by systematic pelvic lymphadenectomy, were retrospectively analyzed. A combined technique with blue dye and radiocolloid was modified in larger tumors to inject the tracer into the residual cervical stroma. RESULTS: The study included 350 patients with stages pT1a - pT2. Macrometastases, micrometastases, and isolated tumor cells were found in 10%, 8%, and 4% of cases. Bilateral detection rate was similar in subgroups with tumors<2cm, 2-3.9cm, and ≥4cm (79%, 83%, 76%) (P=0.460). There were only two cases with false-negative SLN ultrastaging for pelvic LN status among those with bilateral SLN detection. The false negative rate was very low in all three subgroups of different tumor sizes (0.9%, 0.9%, and 0.0%; P=0.999). Sensitivity reached 96% in the whole group and was high in all three groups (93%, 93%, 100%; P=0.510). CONCLUSIONS: If the tracer application technique is adjusted in larger tumors, SLN biopsy can be equally reliable in pelvic LN staging in tumors smaller and larger than 2cm. The bilateral detection rate and false negative rate did not differ in subgroups of patients with tumors<2cm, 2-3.9cm, and ≥4cm.
650    _2
$a adenokarcinom $x diagnóza $x patologie $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a adenoskvamózní karcinom $x diagnóza $x patologie $7 D018196
650    _2
$a spinocelulární karcinom $x diagnóza $x patologie $7 D002294
650    _2
$a falešně negativní reakce $7 D005188
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lymfadenektomie $7 D008197
650    _2
$a lymfatické uzliny $x patologie $7 D008198
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mikrometastázy $7 D061206
650    _2
$a staging nádorů $7 D009367
650    _2
$a pánev $7 D010388
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a biopsie sentinelové lymfatické uzliny $7 D021701
650    _2
$a tumor burden $7 D047368
650    _2
$a nádory děložního čípku $x diagnóza $x patologie $7 D002583
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zikan, M $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Fischerova, D $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Kocian, R $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Germanová, Anna, $d 1981- $7 xx0229091 $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Frühauf, F $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Dusek, L $u Institute for Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Slama, J $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Dundr, P $u Department of Pathology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Němejcová, Kristýna $7 xx0233214 $u Department of Pathology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic.
700    1_
$a Cibula, D $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague, Czech Republic. Electronic address: dc@davidcibula.cz.
773    0_
$w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 148, č. 3 (2018), s. 456-460
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29366509 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20190304110308 $b ABA008
999    __
$a ok $b bmc $g 1339441 $s 1030364
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 148 $c 3 $d 456-460 $e 20180201 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
GRA    __
$a NV16-31643A $p MZ0
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...